Synthorx is a biopharmaceutical company focused on prolonging and improving the lives of people with cancer and autoimmune disorders. Our proprietary, first-of-its-kind platform technology expands the genetic code by adding a new DNA base pair and is designed to create optimized biologics called Synthorins. Based on our preclinical studies, we believe our platform technology can generate a pipeline of additional therapeutics that are differentiated compared to drugs that have been engineered by other means. We are initially using our platform technology to develop cytokine Synthorins that target validated mechanisms of action with large market opportunities, in which existing therapies have significant drawbacks. Our lead product candidate is a variant of IL-2 in development as an immuno-oncology therapeutic. We have additional cytokine Synthorin programs for the treatment of cancer and autoimmune disorders.